E-viri
PDF
Recenzirano
Odprti dostop
-
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae IsolateHumphries, Romney M; Yang, Shangxin; Hemarajata, Peera; Ward, Kevin W; Hindler, Janet A; Miller, Shelley A; Gregson, Aric
Antimicrobial agents and chemotherapy, 10/2015, Letnik: 59, Številka: 10Journal Article
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.
